Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe

Joan Schiller, Dominic Tilden, Michael Aristides, Michael Lees, Adrian Kielhorn, Nikos Maniadakis, Shkun Bhalla

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

In two recent randomised trials, gemcitabine plus cisplatin (Gem/Cis) was found to be at least as effective as vinorelbine plus cisplatin (Vin/Cis), paclitaxel plus cisplatin (Pac/Cis), paclitaxel plus carboplatin (Pac/Carbo), or docetaxel plus cisplatin (Doc/Cis) in patients with advanced non-small cell lung cancer (NSCLC). In cost-minimisation analyses of these studies from the perspectives of the national health services of five European countries (France, Germany, Italy, Spain, UK), Gem/Cis was associated with lower average treatment-related costs than Vin/Cis, Pac/Cis, and Pac/Carbo, and similar or lower costs than Doc/Cis. The incremental cost savings per patient of Gem/Cis compared to Vin/Cis ranged from € 827 to € 2055 per patient and from € 1616 to € 5342 compared to the paclitaxel-containing regimens. Overall, results were generally similar between countries, and were robust to univariate sensitivity analyses. Although differences in healthcare systems mean that the results may not be generalisable to all countries/settings, these results provide an economic rationale for the use of Gem/Cis as a first-line treatment option in Europe for patients with NSCLC.

Original languageEnglish (US)
Pages (from-to)101-112
Number of pages12
JournalLung Cancer
Volume43
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Cisplatin
Costs and Cost Analysis
docetaxel
Carboplatin
Therapeutics
Cost Savings
National Health Programs
Paclitaxel
Health Care Costs
Spain
Italy
France
Germany
Economics

Keywords

  • Chemotherapy
  • Cisplatin
  • Cost-minimisation analysis
  • Gemcitabine
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. / Schiller, Joan; Tilden, Dominic; Aristides, Michael; Lees, Michael; Kielhorn, Adrian; Maniadakis, Nikos; Bhalla, Shkun.

In: Lung Cancer, Vol. 43, No. 1, 01.2004, p. 101-112.

Research output: Contribution to journalArticle

Schiller, Joan ; Tilden, Dominic ; Aristides, Michael ; Lees, Michael ; Kielhorn, Adrian ; Maniadakis, Nikos ; Bhalla, Shkun. / Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. In: Lung Cancer. 2004 ; Vol. 43, No. 1. pp. 101-112.
@article{d138c43e893b45a99a5615dc32381eeb,
title = "Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe",
abstract = "In two recent randomised trials, gemcitabine plus cisplatin (Gem/Cis) was found to be at least as effective as vinorelbine plus cisplatin (Vin/Cis), paclitaxel plus cisplatin (Pac/Cis), paclitaxel plus carboplatin (Pac/Carbo), or docetaxel plus cisplatin (Doc/Cis) in patients with advanced non-small cell lung cancer (NSCLC). In cost-minimisation analyses of these studies from the perspectives of the national health services of five European countries (France, Germany, Italy, Spain, UK), Gem/Cis was associated with lower average treatment-related costs than Vin/Cis, Pac/Cis, and Pac/Carbo, and similar or lower costs than Doc/Cis. The incremental cost savings per patient of Gem/Cis compared to Vin/Cis ranged from € 827 to € 2055 per patient and from € 1616 to € 5342 compared to the paclitaxel-containing regimens. Overall, results were generally similar between countries, and were robust to univariate sensitivity analyses. Although differences in healthcare systems mean that the results may not be generalisable to all countries/settings, these results provide an economic rationale for the use of Gem/Cis as a first-line treatment option in Europe for patients with NSCLC.",
keywords = "Chemotherapy, Cisplatin, Cost-minimisation analysis, Gemcitabine, Non-small cell lung cancer",
author = "Joan Schiller and Dominic Tilden and Michael Aristides and Michael Lees and Adrian Kielhorn and Nikos Maniadakis and Shkun Bhalla",
year = "2004",
month = "1",
doi = "10.1016/j.lungcan.2003.06.003",
language = "English (US)",
volume = "43",
pages = "101--112",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe

AU - Schiller, Joan

AU - Tilden, Dominic

AU - Aristides, Michael

AU - Lees, Michael

AU - Kielhorn, Adrian

AU - Maniadakis, Nikos

AU - Bhalla, Shkun

PY - 2004/1

Y1 - 2004/1

N2 - In two recent randomised trials, gemcitabine plus cisplatin (Gem/Cis) was found to be at least as effective as vinorelbine plus cisplatin (Vin/Cis), paclitaxel plus cisplatin (Pac/Cis), paclitaxel plus carboplatin (Pac/Carbo), or docetaxel plus cisplatin (Doc/Cis) in patients with advanced non-small cell lung cancer (NSCLC). In cost-minimisation analyses of these studies from the perspectives of the national health services of five European countries (France, Germany, Italy, Spain, UK), Gem/Cis was associated with lower average treatment-related costs than Vin/Cis, Pac/Cis, and Pac/Carbo, and similar or lower costs than Doc/Cis. The incremental cost savings per patient of Gem/Cis compared to Vin/Cis ranged from € 827 to € 2055 per patient and from € 1616 to € 5342 compared to the paclitaxel-containing regimens. Overall, results were generally similar between countries, and were robust to univariate sensitivity analyses. Although differences in healthcare systems mean that the results may not be generalisable to all countries/settings, these results provide an economic rationale for the use of Gem/Cis as a first-line treatment option in Europe for patients with NSCLC.

AB - In two recent randomised trials, gemcitabine plus cisplatin (Gem/Cis) was found to be at least as effective as vinorelbine plus cisplatin (Vin/Cis), paclitaxel plus cisplatin (Pac/Cis), paclitaxel plus carboplatin (Pac/Carbo), or docetaxel plus cisplatin (Doc/Cis) in patients with advanced non-small cell lung cancer (NSCLC). In cost-minimisation analyses of these studies from the perspectives of the national health services of five European countries (France, Germany, Italy, Spain, UK), Gem/Cis was associated with lower average treatment-related costs than Vin/Cis, Pac/Cis, and Pac/Carbo, and similar or lower costs than Doc/Cis. The incremental cost savings per patient of Gem/Cis compared to Vin/Cis ranged from € 827 to € 2055 per patient and from € 1616 to € 5342 compared to the paclitaxel-containing regimens. Overall, results were generally similar between countries, and were robust to univariate sensitivity analyses. Although differences in healthcare systems mean that the results may not be generalisable to all countries/settings, these results provide an economic rationale for the use of Gem/Cis as a first-line treatment option in Europe for patients with NSCLC.

KW - Chemotherapy

KW - Cisplatin

KW - Cost-minimisation analysis

KW - Gemcitabine

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0347931813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347931813&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2003.06.003

DO - 10.1016/j.lungcan.2003.06.003

M3 - Article

C2 - 14698544

AN - SCOPUS:0347931813

VL - 43

SP - 101

EP - 112

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -